In analysis of 78 473 cases and 107 143 controls, there was evidence that genetically proxied circulating ANGPTL4 inhibition was associated with a reduced risk of colorectal cancer (odds ratio [OR] per SD decrease = 0.76, 95% confidence interval [CI] = 0.66 to 0.89, P = 5.52 × 10−4) (Table S3). Here, ANGPTL4 is linked to colorectal cancer.